DNDN can ony be used on 25% of the BC patients and at the late stages of BC. Antegin Express is targetting the the other 75% first so it can fast tract through Phase III, as there is no alternative (IMO). We're looking at 6 months of trials instead of two years. Of course the finalizing, FDA reviews, and such add on at least another year for final approval. Big Pharma (BP) will already be at the door way before the FDA finalizes their approval.
Once AE get approval or BP partnership (royalties), then they will also be able to target the 25% of BC patients DNDN is targeting. Here's the kicker - DNDN is used only as a last resort adding only a few addtional months, whereas, AE treatment can be used at the earliest stages. Plus, preventative for those ladies that it is genetically passed on.
This same treatment is currently in Phase I prostate cancer. ?Check out the AE WEB site.
DH
News 
Market Data 
Discover 
